Photo of Raymond C. Bergan, M.D.

Raymond C. Bergan M.D.

    • Professor of Medicine School of Medicine
    • Associate Director, Medical Oncology OHSU Knight Cancer Institute School of Medicine
    • Co-leader, Translational Oncology Program OHSU Knight Cancer Institute School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

At Northwestern University, Dr. Bergan led a research team that expanded the understanding of how early stage cancer cells transform to travel throughout the body. His laboratory was the first to use drugs to target this form of disease progression in humans. Understanding the changes that enable the spread of the disease is essential to saving lives; metastasis is a leading cause of death in cancer patients.

At the OHSU Knight Cancer Institute, Dr. Bergan has established a research laboratory continuing this work as part of his role in overseeing the division. Among his other patient care and research priorities will be expanding the institute’s offering of early phase drug trials and applying the latest drug development. His goal is to work with the OHSU Knight Cancer Institute’s team of researchers to provide highly tailored treatments to patients, including those of early or advanced cancer, and, ultimately, change the course of their disease.

OHSU faculty research collaborators
Joe Gray, Lisa Coussens, Pepper Shedin, Thomaz Beer, Joshi Alumkal, Chris Corless, Shannon McWeeney, Sara Courtneidge


  • M.D., State University of New York, Syracuse New York 1987
  • Residency:

    • Internal Medicine – State University of New York, Syracuse, N.Y., 1990
  • Fellowship:

    • Medical Oncology – National Cancer Institute, Medicine Branch, Bethesda, Md., 1993
  • Certifications:

    • American Board of Internal Medicine, Medical Oncology (1993, 2004, 2014)

Memberships and associations

  • Associate American College of Physicians


  • "Soy isoflavones for breast cancer risk reduction - Response" Cancer Prevention Research July 2012
  • "p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion" Oncogene July 31 2003
  • "Gene Expression Profiling of Renal Medullary Carcinoma" Cancer March 1 2004
  • "Improved intracellular delivery of oligonucleotides by square wave electroporation" Nucleic Acid Therapeutics  2001
  • "Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin" Clinical and Experimental Metastasis  1996
  • "Pharmacokinetics of thalidomide in an elderly prostate cancer population" Journal of Pharmaceutical Sciences January 1999
  • "HTLV-I-associated disease" Internal Medicine for the Specialist  1991
  • "Associations of serum carotenoid levels with serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in black men and white men" Cancer Epidemiology Biomarkers and Prevention December 1 2007
  • "A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (Valspodar)" Cancer September 15 2001
  • "Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides" Nucleic Acid Therapeutics  1995
  • "Spectral biomarkers for chemoprevention of colonic neoplasia" Gut October 26 2015
  • "Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells" Leukemia  1999
  • "Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)" Prostate September 15 1998
  • "A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in Situ of the breast" Clinical Cancer Research July 15 2014
  • "Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy" Nucleic Acids Research July 25 1993
  • "Diminished expression of h2-calponin in prostate cancer cells promotes cell proliferation, migration and the dependence of cell adhesion on substrate stiffness" FEBS Open Bio  2014
  • "Crystal structure of a type II dehydroquinate dehydratase-like protein from Bifidobacterium longum" Journal of Structural and Functional Genomics March 2013
  • "How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? [7]" Blood  1996
  • "Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer" Journal of the National Medical Association September 1997
  • "Soy isoflavone supplementation for breast cancer risk reduction" Cancer Prevention Research February 2012
  • "The Ninth Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research" Cancer Prevention Research April 2011
  • "Androgen receptor-independent function of FoxA1 in prostate cancer metastasis" Journal of Cancer Research June 15 2013
  • "In vitro models of prostate apoptosis" The Prostate. Supplement  2000
  • "Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells" Prostate Cancer and Prostatic Diseases  2001
  • "Some aspects of analysis of gene array data." Cancer Treatment and Research  2002
  • "An analysis of gene array data related to cell adhesion and prostate cancer." Cancer Treatment and Research  2002
  • "Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer" American Journal of Medicine  1995
  • "Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity" Molecular Pharmacology February 1997
  • "Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer" Cancer June 1 2006
  • "Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability" Small June 5 2009

Additional information

Edit profile